Invention Grant
- Patent Title: CD73 inhibitors
-
Application No.: US16481146Application Date: 2019-02-22
-
Publication No.: US11028074B2Publication Date: 2021-06-08
- Inventor: Robert Dean Dally , Maria Cristina Garcia Paredes , Lawrence Joseph Heinz, II , Jennifer Marie Howell , Frank George Njoroge , Yan Wang , Genshi Zhao
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Michael R. Asam
- International Application: PCT/US2019/019074 WO 20190222
- International Announcement: WO2019/168744 WO 20190906
- Main IPC: C07D403/04
- IPC: C07D403/04 ; A61P35/00
Abstract:
The present invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer.
Public/Granted literature
- US20210002257A1 CD73 INHIBITORS Public/Granted day:2021-01-07
Information query
